RadNet (NASDAQ:RDNT) Stock Moved Down to Hold by Zacks Research

Zacks Research lowered shares of RadNet (NASDAQ:RDNT) from a strong-buy rating to a hold rating in a research report report published on Monday morning,Zacks reports.

A number of other brokerages have also recently issued reports on RDNT. Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a research report on Friday, July 31st. Raymond James Financial reaffirmed a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Truist Financial lifted their price target on RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of RadNet in a research note on Wednesday, November 4th. Finally, Barclays increased their price objective on RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a report on Friday, August 28th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $90.43.

RadNet Price Performance

Shares of NASDAQ:RDNT opened at $77.94 on Monday. RadNet has a 12 month low of $50.82 and a 12 month high of $85.84. The firm has a market capitalization of $6.13 billion, a P/E ratio of -268.76 and a beta of 1.42. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.49 and a quick ratio of 1.48. The company’s fifty day moving average price is $72.69 and its 200 day moving average price is $65.45.

RadNet (NASDAQ:RDNT) last released its quarterly earnings data on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.08. The company had revenue of $638.26 million during the quarter, compared to the consensus estimate of $639.97 million. RadNet had a negative net margin of 0.94% and a positive return on equity of 3.14%. RadNet’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.20 earnings per share. As a group, sell-side analysts predict that RadNet will post 0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RadNet

A number of hedge funds and other institutional investors have recently made changes to their positions in RDNT. BlackRock Inc. purchased a new stake in shares of RadNet during the second quarter worth approximately $675,768,000. JB Capital Partners LP purchased a new position in RadNet during the 2nd quarter worth $87,821,842. Bamco Inc. NY purchased a new position in RadNet during the 2nd quarter worth $77,765,000. Punch & Associates Investment Management Inc. acquired a new stake in shares of RadNet in the 2nd quarter worth $39,054,000. Finally, Deutsche Bank AG purchased a new stake in shares of RadNet in the second quarter valued at about $30,586,000. Hedge funds and other institutional investors own 77.90% of the company’s stock.

Key Headlines Impacting RadNet

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported third-quarter EPS of $0.30, above the $0.22 consensus, while revenue rose 22.1% year over year. It also raised its 2026 revenue outlook to $2.5 billion–$2.6 billion; reports described this as the third consecutive quarterly guidance increase. RadNet Q3 earnings and outlook
• Positive Sentiment: The planned ONRAD acquisition would give RadNet direct access to more than 225 hospitals and expand its inpatient reach. One analysis said ONRAD’s EBITDA margins above 30% could make the deal margin-accretive. Separately, Digital Health’s year-to-date contract value reached $108 million. RadNet: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: KeyCorp raised its price target to $95 from $92 and maintained an Overweight rating, signaling analyst confidence in further upside. KeyCorp stock recommendations
• Neutral Sentiment: A short-interest report stated that short interest totaled zero shares as of November 10, despite describing it as a large increase. The reported figure and description appear inconsistent, so this is not a clear trading signal.
• Negative Sentiment: Quarterly revenue of $638.26 million came in slightly below the $639.97 million analyst estimate, and RadNet reported a negative net margin. These factors may have offset some of the otherwise strong results.

RadNet Company Profile

RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.